INTEGRA Biosciences has recently awarded 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips, and various lab accessories to HilleVax to support its research into norovirus vaccine development. The prize, part of the ‘INTEGRA supports start-ups’ competition, will provide the company with the necessary resources to accelerate its vaccine candidate to licensure.

HilleVax, a start-up founded to develop novel vaccines, aims to address health inequalities and equalize care for patients globally. Stemming from a collaboration between Frazier Healthcare and Takeda, HilleVax is focused on advancing HIL-214, a virus-like particle vaccine candidate for norovirus currently in Phase II clinical trials.

The company is in the process of establishing its laboratory to further the development of HIL-214 and is excited about winning the ‘INTEGRA supports start-ups’ competition. Dr. Erika Olson, Senior Scientist in the company’s Clinical Assay Group, expressed her enthusiasm about the award, highlighting the ergonomic design and efficiency of INTEGRA products.

INTEGRA Biosciences’ support for HilleVax’s research aligns with the company’s commitment to advancing healthcare and laboratory technology. The partnership reflects a shared dedication to innovation and progress in the field of vaccine development.

For more information on HilleVax and its use of INTEGRA’s liquid handling solutions, visit the link here.